SPRB Earnings

SPRB reported its FY2025Q4 earnings on 2026-02-16, showcasing a revenue of against an estimate of 10.76M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -13.48 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following SPRB's FY2025Q4 earnings announcement on 2026-02-16, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, SPRB's stock price tends to shift by an average of +1.44% in the 10 days leading up to earnings and -8.74% in the 10 days following, providing insight into potential market.

For , analysts estimate SPRB’s annual revenue to reach , while the EPS is projected at -12.31. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates No Change by 0% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between SPRB's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved No Change by 0% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, SPRB's stock price typically moves by +1.44% in the 10 days before its earnings and -8.74% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -12.31 and revenue of .

The earnings call highlights several concerns: missed EPS expectations, financial constraints, and regulatory risks. Although there is optimism about FDA approval pathways and potential market size, the lack of a shareholder return plan and financial uncertainty weigh heavily. The Q&A session did not alleviate concerns, as management's responses were vague about financial planning and patient identification. Given these factors, the sentiment leans negative, with a likely stock price decline of -2% to -8% over the next two weeks.